Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Want to see AU:IXC full AI Analyst Report?
IXC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.18
Previous CloseN/A
Volume14.00K
Average Volume (3M)49.57K
Market Cap
AU$6.84M
Enterprise ValueAU$3.67M
Total Cash (Recent Filing)AU$5.38M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding75,153,850
10 Day Avg. Volume15,093
30 Day Avg. Volume49,574
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.28
Price to Sales (P/S)29.41
P/FCF Ratio-10.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt reduces refinancing and interest burdens, improving financial flexibility. For a clinical-stage biotech, being debt-free lowers near-term liquidity strain and preserves optionality to fund trials or negotiate partnerships without fixed debt service, supporting strategic choices over the medium term.
Improving Cash Outflow TrendA sizable reduction in cash outflow and narrower losses versus the prior year indicate management is slowing burn. If sustained, this durable trend can extend runway, reduce reliance on frequent external raises and give management time to advance clinical milestones or attract non-dilutive partners.
Focused Lead Clinical Program (IIH)A concentrated R&D focus on a single lead program targeting IIH provides a clear development pathway and resource allocation. For a small biotech, this clarity improves operational efficiency, makes clinical progress easier to communicate to partners, and can create binary long-term value if regulatory milestones are achieved.
Bears Say
Sharp Revenue DeclineAn ~81% revenue drop signals highly volatile and shrinking top-line performance. For a company without commercial products, this undermines self-funding prospects, forces greater dependence on external capital to progress trials, and suggests structural challenges in converting R&D into recurring revenue.
Persistent Negative Cash GenerationConsistently negative operating and free cash flow demonstrates ongoing cash burn and an inability to finance operations internally. This structural weakness necessitates repeated funding rounds or partners, increasing dilution risk and creating uncertainty about the firm's ability to sustain development programs long-term.
Ongoing Losses And Declining EquitySustained operating and net losses coupled with a falling equity base reflect value erosion and reduced balance-sheet cushioning. Over several quarters this raises vulnerability to adverse events and heightens the likelihood of dilutive capital raises, which can materially impact shareholder value and strategic flexibility.
Invex Therapeutics Ltd. News
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.07 and its highest was AU$0.18 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$6.84M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 61 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Feb 12, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.72%
12-Months-Change
Fundamentals
Return on Equity
-17.07%
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Technical Analysis
Alterity Therapeutics
―
AnteoTech Ltd
―
AdAlta Ltd.
―
Chimeric Therapeutics Ltd.
―
Recce Pharmaceuticals Ltd.
―